- Home
- GHRS vs MGTX Comparison
GHRS vs MGTX Comparison
Compare GHRS & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHRS
- MGTX
- Stock Information
- Founded
- GHRS 2018
- MGTX 2015
- Country
- GHRS Ireland
- MGTX United States
- Employees
- GHRS N/A
- MGTX N/A
- Industry
- GHRS Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GHRS Health Care
- MGTX Health Care
- Exchange
- GHRS Nasdaq
- MGTX Nasdaq
- Market Cap
- GHRS 774.1M
- MGTX 670.2M
- IPO Year
- GHRS 2021
- MGTX N/A
- Fundamental
- Price
- GHRS $13.11
- MGTX $7.83
- Analyst Decision
- GHRS Strong Buy
- MGTX Strong Buy
- Analyst Count
- GHRS 9
- MGTX 2
- Target Price
- GHRS $29.33
- MGTX $24.00
- AVG Volume (30 Days)
- GHRS 319.1K
- MGTX 385.8K
- Earning Date
- GHRS 11-13-2025
- MGTX 11-12-2025
- Dividend Yield
- GHRS N/A
- MGTX N/A
- EPS Growth
- GHRS N/A
- MGTX N/A
- EPS
- GHRS N/A
- MGTX N/A
- Revenue
- GHRS N/A
- MGTX $37,917,000.00
- Revenue This Year
- GHRS N/A
- MGTX $144.79
- Revenue Next Year
- GHRS N/A
- MGTX $168.58
- P/E Ratio
- GHRS N/A
- MGTX N/A
- Revenue Growth
- GHRS N/A
- MGTX 366.84
- 52 Week Low
- GHRS $6.72
- MGTX $4.23
- 52 Week High
- GHRS $20.50
- MGTX $8.98
- Technical
- Relative Strength Index (RSI)
- GHRS 47.63
- MGTX 45.31
- Support Level
- GHRS $12.26
- MGTX $8.20
- Resistance Level
- GHRS $13.65
- MGTX $8.95
- Average True Range (ATR)
- GHRS 0.75
- MGTX 0.44
- MACD
- GHRS -0.08
- MGTX -0.04
- Stochastic Oscillator
- GHRS 31.37
- MGTX 22.41
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.